2. GPCR/G Protein
  3. Formyl Peptide Receptor (FPR)
  4. Annexuzlimab

Annexuzlimab 是一种人源化 IgG1 单克隆抗体，可特异性结合 ANXA1，从而干扰其与甲酰肽受体 1 和 2 (FPR1/2) 的相互作用。Annexuzlimab 阻滞细胞周期进程，导致癌细胞在 G1 期累积。Annexuzlimab 靶向分泌的 ANXA1，阻止 FPR1/2 的激活，从而减少癌症进展。Annexuzlimab 可用于三阴性乳腺癌、胰腺癌和骨肉瘤的研究。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Annexuzlimab

Annexuzlimab Chemical Structure

1.  客户无需承担相应的运输费用。

2.  同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户。

规格 是否有货
1 mg   询价  
5 mg   询价  
10 mg   询价  

* Please select Quantity before adding items.

Customer Review

Annexuzlimab 相关抗体

Top Publications Citing Use of Products

  • 生物活性

  • 纯度 & 产品资料

  • 参考文献

生物活性

Annexuzlimab is a humanised IgG1 monoclonal antibody which specifically binds to ANXA1 disrupting its interaction with formyl peptide receptors 1 and 2 (FPR1/2). Annexuzlimab arrests cell cycle progression with cancer cells accumulating in the G1 phase. Annexuzlimab targets secreted ANXA1, preventing FPR1/2 activation and reducing cancer progression. Annexuzlimab can be used for the research of triple negative breast cancer, pancreatic cancer and osteosarcoma[1][2].

同型

Human IgG1 kappa
推荐同型对照抗体
反应种属

Human
IC50 & Target

Annexin A1/ANXA1
体外研究
(In Vitro)

Annexuzlimab (MDX-124) (2.5-10 μM；72 h) 以剂量依赖性方式显著降低表达 ANXA1 的人类癌细胞系的增殖能力，其中 10 μM 在部分乳腺癌和卵巢癌细胞系中可导致 >50% 的活力下降，但对不表达 ANXA1 的肺癌细胞系无影响[1]。
Annexuzlimab (10-25 μM；24 h) 可诱导剂量依赖性的 G1 期细胞周期阻滞，其中 25 μM 的作用最为显著 (MDA-MB-231 细胞 G1 期增加 33.5%，A549 细胞增加 21.2%，BxPC-3 细胞增加 10.8%)，且不诱导细胞凋亡[1]。
Annexuzlimab (5 μM；72 h) 不会诱导 MCF-7 乳腺癌细胞或 Caco-2 结直肠癌细胞发生凋亡[1]。
Annexuzlimab 处理骨肉瘤细胞系可显著抑制细胞生长，其机制是通过剂量依赖性的细胞周期阻滞，并显著降低骨肉瘤细胞系的迁移能力[2]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Annexuzlimab 相关抗体:

Cell Proliferation Assay[1]

Cell Line: MCF-7, HCC1806, MDA-MB-231, MCF-7/TAMR7, BxPC-3, MIA PaCa-2, PANC-1, A2780, A2780cis, A2780ADR, Caco-2, HCT116, SW480, NCI-H69/CPR, A549, COR-L23, COR-L23.5010
Concentration: 2.5-10 μM
Incubation Time: 72 h
Result: Caused a significant dose-dependent reduction in cellular proliferation in all ANXA1-expressing breast, pancreatic, ovarian, colorectal, and some lung cancer cell lines compared to IgG1 isotype control; At 10 μM, MCF-7, HCC1806, and MDA-MB-231 had >50% viability reduction, MCF-7/TAMR7 had 21% reduction, BxPC-3 had 40% reduction, MIA PaCa-2 had 20% reduction, PANC-1 had 34% reduction, A2780 had 31% reduction, A2780cis had 48% reduction, A2780ADR had 72% reduction, Caco-2, HCT116, and SW480 had significant reduction, NCI-H69/CPR had 36% reduction, A549 had 37% reduction; Showed no anti-proliferative activity in non-ANXA1-expressing COR-L23 and COR-L23.5010 lung cancer cells.

Cell Cycle Analysis[1]

Cell Line: BxPC-3, MIA PaCa-2, MDA-MB-231, A549
Concentration: 10 μM, 25 μM
Incubation Time: 24 h
Result: Induced a dose-dependent G1 phase cell cycle arrest compared to untreated control cells; At 25 mM, MDA-MB-231 had a 33.5% increase in G1 phase and 29.1% decrease in S phase, A549 had a 21.2% increase in G1 phase and 18.3% decrease in S phase, BxPC-3 had a 10.8% increase in G1 phase and 10.4% decrease in S phase; Did not induce apoptosis (no sub G0/G1 peak observed).

Apoptosis Analysis[1]

Cell Line: MCF-7, Caco-2
Concentration: 5 μM
Incubation Time: 72 h
Result: Showed no significant difference in the percentage of early or late apoptotic/necrotic cells compared to untreated control cells.
体内研究
(In Vivo)

Annexuzlimab (1 mg/kg; i.v.; 在第 1 天和第 8 天给药) 在 BALB/c 小鼠三阴性乳腺癌模型中抑制肿瘤生长 (肿瘤生长抑制率为 23%) [1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: BALB/c (female, 9 weeks old, orthotopic inoculation with 4T1-luc murine triple-negative breast cancer cells)[1]
Dosage: 1 mg/kg
Administration: i.v.; two doses on day 1 and day 8
Result: Significantly inhibited tumour growth versus vehicle control, achieving 23% tumour growth inhibition by day 15. Observed no noticeable change in body weight throughout the study.
基因 ID

301  [NCBI]

Accession

P04083
应用

ELISA, FACS, Functional assay
偶联物

Unconjugated
复溶方法

The product can be reconstituted/diluted with sterile PBS or saline.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
纯度 & 产品资料
参考文献

Annexuzlimab 相关分类

  • 摩尔计算器

  • 稀释计算器

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量   浓度   体积   分子量 *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

浓度 (start) × 体积 (start) = 浓度 (final) × 体积 (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

AnnexuzlimabMDX-124MDX124MDX 124Formyl Peptide Receptor (FPR)triple negative breast cancerAnnexin-A1FPR1/24T1-luc syngeneic mouse modelANXA1formyl peptide receptors 1 and 2osteosarcomaG1 phaseOS cell linesBALB/c mice modelInhibitorinhibitorinhibit

您最近查看的产品:

Your information is safe with us. * Required Fields.

   产品名称：

  

* 需求量：

* 客户姓名：

 

* Email：

* 电话：

 

* 公司或机构名称：

   留言给我们：

Bulk Inquiry

Inquiry Information

产品名称：
Annexuzlimab
目录号：
HY-P991864
需求量：

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

   产品名称：

  

* Lot #：

* 客户姓名：

 

* Email：

   电话：

 

* 部门：

* 公司或机构名称：

 

   留言给我们：

Request for HNMR Report

We have received your request and will respond to you as soon as possible.

嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z